InsidersTradesSigma
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Browse the detailed record of transactions filed by Doyle John Brendan. Director active across 1 company, notably Cognition Therapeutics INC. Cumulatively, 6 reports have been recorded. History available since 1 May 2023. The latest transaction was disclosed on 1 May 2025 (Retenue fiscale). Regulator: SEC (Form 4). The full history is openly available.
6 of 6 declarations